Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Inhibikase Therapeutics, with a price target of $8.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jason McCarthy has given his Buy rating due to a combination of factors including Inhibikase Therapeutics’ financial position and strategic advancements. The company reported a net loss of $9.9 million for the second quarter of 2025 but maintains a strong cash position of $87.7 million, which is projected to support operations through the fourth quarter of 2026. This financial stability is crucial as the company prepares to launch its Phase 2b study for its lead asset, IKT-001, in the treatment of pulmonary arterial hypertension (PAH).
In addition, the upcoming Phase 2b study, named ‘IMPROVE-PAH,’ is a significant milestone for Inhibikase. The study is designed as a multi-center, randomized, double-blind, placebo-controlled trial, targeting the enrollment of approximately 150 PAH patients. The trial aims to evaluate the efficacy of IKT-001, a next-generation prodrug of imatinib, over a 26-week treatment period. The innovative design and promising safety profile of IKT-001, which has shown enhanced gastrointestinal absorption and reduced side effects in preclinical studies, further support the positive outlook and Buy rating from McCarthy.